Abstract: Hyaluronic acid fi llers have become popular soft tissue fi ller augmentation agents over the past several years. They have helped revolutionize the fi ller market with a number of new products available for use for our patients. The purpose of this manuscript is to review the characteristics of the HA fi llers and to review each of the current products currently available for use in the US.
Introduction
The last several years have seen a number of new soft tissue augmentation products (to be commonly called "fi llers") emerge into the armamentarium of products used by physicians in the treatment of the signs of aging. These products have become increasing popular since the advent of the use of botulinum toxin, type A, for the treatment of expression lines, mainly of the upper one third of the face. In fact, in a recent survey conducted by the American Society for Aesthetic Plastic Surgery (ASAPS), the number one non-surgical procedure being performed currently in the US is the injection of botulinum toxin, type A, whereas the fi fth most common procedure is now the injection of hyaluronic acid (HA) fi llers, the topic of this manuscript. ASAPS data currently rank the injection of botulinum toxin number one, laser hair removal number two, chemical peels number three, microdermabrasion number four, and HA fi llers number fi ve. The numbers also represent a 12.3% increase over the use of bovine and human collagen treatments over the previous year and approximately 48% of all dermal fi ller procedures being performed (www.surgery.org/public).
The hallmark of the aging face is loss of associated subcutaneous volume over time. Clinically, with this loss, one commonly fi nds the signs most clinicians see routinely when confronted with a patient concerned with the aging face -an increase in facial vasculature and pigment alterations, as well as an increase in the lines and wrinkles of the skin. This is associated histologically with a thinning of the epidermis and with dermal atrophy and loss of the elastic tissues present within the dermis and with actinic changes with loss of dermal collagen. The treatment for this change over time can be multiple, from skin care products, to energy based therapies (lasers, light sources, and radiofrequency devices) to fi llers and toxins. HA fi llers play an integral part in the correction of changes associated with aging; especially those associated in the lower one-half of the face, from the nasolabial folds, to the vertical lip lines of the lips, the marionette lines around the mouth, and in the thinning of the lip itself. They also can be used for volume enhancement of the cheeks.
The concept of an ideal fi ller has been debated for a number of years. Without question, everyone wants the ideal fi ller to be easy to inject, produce reproducible results, and have longevity (lasting between 1 and 2 years). Further, the ideal fi ller would be painless on injection and nonallergenic (no skin tests required), noncarcinogenic, nonteratogenic, and we would expect it not to migrate once injected into the skin. We would like the ideal fi ller to be stored at room temperature, have a long shelf-life, and be free from all transmittable diseases. Further, we would want this ideal fi ller to have few, if any local adverse events, and be affordable to both the patient and the physician. And fi nally, we want the material to last, with a debate still ongoing between those fi llers which are temporary and those fi llers which are permanent. It is beyond the scope of this document to pursue further the temporary versus permanent debate. We are closer than ever with the advent of the HA fi llers.
Zyderm
® and Zyplast
®
In order to understand the HA fi llers and their prominent role in the marketplace, we must spend a little time reviewing the past and some of the other fi ller products on the market. The fi rst synthetic group of fi llers was the bovine derived collagen products, namely Zyderm ® and Zyplast ® collagen. The collagen material was derived from a closed herd of cattle and purifi ed for human use. All of the collageninjectable materials contain lidocaine, to ease any associated pain which may be associated with the injection technique. Zyderm ® I, fi rst approved by the FDA in 1981, is a 3.5% by weight bovine dermal collagen, in a suspension of phosphatebuffered physiologic saline. Zyderm ® I is recommended for injection into the superfi cial papillary dermis and was approved for the treatment of superfi cial lines and wrinkles as well as shallow acne scars. Zyderm ® II, FDA approved in 1983, contains 6.5% by weight bovine dermal collagen in a similar buffered saline suspension. Most clinicians felt this material was best used to treat acne or traumatic scars on the face, although it worked well for lines and wrinkles, too. Its injection should be into the papillary dermis. Zyplast ® , FDA approved in 1985, is a 3.5% by weight bovine dermal collagen cross-linked with glutaraldehyde, making it more resistant to biodegradation after injection. Zyplast ® is best injected into the mid-deep dermis and its recommended use is for deep lines and folds (Narins and Bowman 2005; Eppley and Dadvand 2006) .
Overcorrection of the defect is necessary with both of the Zyderm ® products because of the buffered saline contained within the syringes. Because of the animal nature of the material, it was necessary to perform intradermal skin testing prior to the injection procedure. From early studies, it became clear that double skin testing, that is, skin testing on each forearm 4 weeks apart, reduced the apparent risk of allergy or hypersensitivity to a very small percentage. Still, even with double skin testing, approximately 3% of patients treated may develop hypersensitivity to the bovine collagen. Other adverse events, which are reported, include local effects such as erythema, induration, and pruritus at the injection sites. More rare side-effects have included granuloma formation and necrosis secondary to vascular occlusion. It was also realized that, although the standard injectable materials from the early 1980s up until the end of the 1990s, these materials were variable in their longevity, with most clinicians noting an approximate 3-month duration with the collagen products. 
CosmoDerm

HA fi llers
In the US, physicians were "content" using US collagenbased products for the treatment of lines and wrinkles, folds, and furrows associated with the aging face throughout the 1980s and the 1990s. In Europe, however, a revolution was taking shape, with products being developed that would soon change how the majority of US doctors would utilize fi llers for our patients. This revolution began with the development of the HA fi llers, the topic of the remainder of this manuscript.
A number of HA fi llers are available in the US for use as fi ller materials; many more are under development process at the time of writing. Table 1 lists the HA fi llers that are available and/or are under development. In order to fully understand the scope of HA fi llers, and to determine which HA fi ller may be best for a particular patient, a review of the basic characteristics and terms are necessary. HA, or hyaluronan, by defi nition, is a glycosaminoglycan which consists of regular repeating non-sulfated disaccharide units of glucuronic acid and N-acetylglucosamine (Alberts et al 2002) . HA is a naturally occurring substance, a biopolymer, which exhibits no species and no tissue specifi city. HA is an essential component of the extracellular matrix of all animal tissues and is an abundant component of this matrix. HA is highly hydrophilic, that is, it attracts water, and this helps it form large concentrations that can occupy a large volume relative to its mass. It has been shown to form gels at even low concentrations. When water is drawn into the HA matrix, it has been shown to create a swelling pressure or turgor that enables the HA complex to withstand compressive forces. Thus it has been found useful as a fi ller in treating some of the signs of aging. The fact that HA exhibits no tissue or species specifi city is crucially important to minimize any untoward effect for potential immunologic reactions or transplantation rejection. The fi rst HA developed as a dermal fi ller was in 1989 by Balazs (Balazs and Denlinger 1989) , who understood the biocompatibility of this class of compounds and lack of immunogenicity. The product was not long lasting, but the revolution had begun.
The main differentiators for HA fi llers are: source of HA; concentration of HA in each syringe being utilized; the particulate size of the HA; whether the HA is cross-linked; the type of cross-linking agent used in the HA; whether the HA is monophasic or biphasic; and whether there is an anesthetic in the HA syringe. The HA source for the available fi llers are either avian, that found primarily in rooster combs, or from bacteria-sourced HA, mainly from the synthetic fermentation of the Staphylococcus equine bacterium. This latter source has become more popular recently because of potential allergy to the avian source owing to a high avian protein content, and because the bacterial-derived HA products are more pure, more viscous, and not derived from an animal source. The concentration of HA fi llers is also important.
Those HA fi llers with higher HA concentrations displace more tissue and are felt to equate to longer duration of effect. Those HA fi llers with concentrations of 20 mg/g or more of HA are now considered ideal. All HA fi llers utilize a single ether cross-link bond to stabilize the product. The newer non-particulate HA fi llers are either double cross-linked, multi crossed-linked, or monophasic gels. They are crosslinked with a single ether bond and have their long chains of HA bound to 1,4-butandiol diglycidylether (BDDA) as well as having the shorter HA chains bound to the network, also with BDDA. The resulting homogeneous mass becomes potentially less resistant to degradation, making for a longerlasting HA fi ller. As a result of these processes, and because these newer gels are non-particulate in formation, they require a higher HA concentration for the duration of effect. The cross-linking of HA is required to prevent biodegradation from free radicals and enzymes and to increase the HA fi ller duration. BDDA, as already mentioned, has been utilized with much success. A newer agent, 1, 2, 7, 8-diepoxyoctane, may further enhance duration. Larger HA particles tend to last longer and are usually used for deeper dermal injections and defects. Monophasic HA fi llers are cohesive gels rather than just HA particles. Biphasic HA fi llers are made into particle form. Each form has proponents -monophasic HA fi llers may last longer and may not migrate after injection; biphasic HA fi llers can be customized to particle size per indication and anatomic area being treated (Medical Insight Inc 2006 Plus is also 4.5-6.0 mg/mL but the particle size is increased, to 750 um. Unfortunately, longevity with this product too is in the 3-to 4-month range. Local adverse reactions with the product are not usually signifi cant, a benefi t for those requiring a "quick fi x" type of procedure (Manna et al 1999; Monheit 2004 ® is a non-animal stabilized HA, known as NASHA, produced from the fermentation of equine streptococci. It is cross-linked with BDDA, with a 1% degree of cross-linking. The HA concentration of Restylane ® is 20 mg/mL and its gel particle size is 400 μm. Restylane ® has a particulate size of 100,000 gel particles per milliliter and is the only HA fi ller in this family approved in the US at the time of this writing. Its FDA approval is for mid-dermal applications such as deep wrinkle correction, lip augmentation, nasolabial fold correction, and for glabellar creases. Restylane ® has also been used with success in the treatment of tear trough deformities. Other Restylane ® products available in other countries and in clinical testing in the US include Restylane ® Perlane ® (8000 gel particles/mL) for deeper injections and deeper defects, and Restylane ® Fine Lines (200,000 gel particles/mL) for superfi cial injections and superfi cial defects (Matarasso et al 2006) .
The use of Restylane ® in clinical trials date back to the 1990s. In two separate European studies, by Duranti et al (1998), and Olenius (1998) , duration of effect were evaluated and found to be 78% maintaining moderate to marked improvement at 8 months in the study by Duranti; HA fi llers for the aging face and 82% and 69% correction after 12 weeks and 26 weeks respectively in the study by Olenius. Both of these studies reported injection-related reactions, including treatmentsite erythema, hyperpigmentation at the treatment site, and pain from the injection itself of about 13%. Further analysis and study of injectors from Europe in 1999 yielded an improvement in adverse events, with only 0.15% of patients experiencing localized cutaneous reactions (Friedman et al 2002) . Several cases of delayed implant hypersensitivity were reported in the European experience (0.4%-3.7%) prompting the manufacturers to introduce a more purifi ed product in 1999 (Lowe et al 2001; Lupton et al 2001; Micheels 2001) . Further evaluation from the European groups showed that with the new purifi ed product, adverse events were reduced to 0.06% and hypersensitivity reactions were reduced to 0.02%. From this experience and low incidence of hypersensitivity reactions, no skin testing is required for the Restylane ® available in the US. The pivotal US clinical trial from Narins et al (2003), compared Restylane ® in one nasolabial fold with Zyplast ® collagen in the other fold. The study utilized 138 predominantly female and Caucasian individuals to receive treatment with both materials, one in each nasolabial fold. Patients returned at 2-week intervals for further treatment until both sides of the face reached optimal correction. The average number of treatment sessions required to achieve this optimal result was 1.4 for both products. The volume needed for correction was lower with Restylane ® (mean 1.0 mL; range 0.3-2.8 mL) than for Zyplast ® (mean 1.6 mL; range 0.1-5.0 mL). The Wrinkle Severity Rating Scale score for Restylane ® was superior at all time points (2, 4, and 6 months after baseline), and at 6 months after baseline: Restylane ® was rated superior in 56.9% of patients compared with Zyplast ® , in 9.5% of patients. The Global Aesthetic Improvement Scale rating was also superior for Restylane ® at all time points, with 62% rating Restylane ® superior at 6 months compared with Zyplast ® , with only 8% rating Zyplast ® superior to Restylane ® . Adverse events were recorded at each time visit during the clinical study. Mild or moderate injection site reactions occurred in a similar non-statistical fashion with both of the injectable projects (93.5% with Restylane ® and 90.6% with Zyplast ® ). During the 6 month follow-up period, treatment-related adverse events were reported to be 26.4% for Restylane ® and 39.1% for Zyplast ® . Delayed-onset reactions were noted in 8.7% of patients -all resolved within 2-3 months without treatment. No hypersensitivity reactions were reported during the clinical trial. viscosity HA fi llers. They were FDA approved in June, 2006 -Juvederm ™ Ultra for deep wrinkles and defects, Juvederm ™ Ultra Plus for deeper furrows, such as the nasolabial folds. The Juvederm ™ family is produced from the bacterial fermentation of equine streptococci. The HA is cross-linked with a patented single-phase BDDE-phosphate buffered to 6.5-7.3 pH. With a higher concentration of HA and more cross-linking than other HA fi llers, it is felt by some injectors that perhaps the Juvederm ™ family of products may persist longer than other HA fi llers and have a more smooth injection fl ow (Medical Insight Inc 2006) , although clinical studies documenting these claims have not been performed in a head-to-head comparison against any of the other available HA fi llers.
The pivotal US clinical trial, by Baumann et al (2006) , was a comparison of Juvederm ™ products with Zyplast ™ collagen in the treatment of nasolabial folds. Four hundred and twenty-three patients completed the clinical trial of a 24-week evaluation. Over three hundred of the patients received an additional treatment of the HA fi ller at the conclusion of the clinical trial which looked at long-term effi cacy. Results showed that both of the fi llers used showed signifi cant improvements at all points during the course of the 24-week clinical trial. The Juvederm ™ products studied showed signifi cantly greater effi cacy than the bovine collagen product; the effi cacy increased with time and was greatest at 24 weeks after the last treatment. Utilizing a 4 point scale,
an improvement of at least 1 point was seen in more than 80% of Juvederm ™ -treated patients compared with a 0.5 improvement, on average, in the Zyplast ™ -treated patients. For those having an end of 24 week injection, long-term results showed that 57% had duration of effect at 8 months, 37% at 10 months, and 18% at 12 months.
Adverse 
Belotero
The other HA fi ller currently being investigated is known as Belotero, manufactured by Merz Pharmaceuticals (Germany, Raleigh, NC, US). It is a non-animal, monophasic cross-linked gel. It utilizes 22.5 mg/mL HA in a patented matrix technology. It is also undergoing clinical testing in the US market.
Other HA fi llers will also be coming to the US over the next several years. There are numerous of these products available in Europe and looking for a home in the US. Most of the major pharmaceutical companies are looking to partner with these European companies and to bring their technology into the aesthetic US market. We, as physicians, will have many options for fi llers in the near future. This is good for physicians, as the prices for these fi llers should become more reasonable, and better for their patients, where optimal fi llers can be utilized for the many needs and defects for which they can be utilized.
Currently, physicians have a choice of only a handful of HA fi llers available for use for these patients. Most of our patients are familiar with Restylane ® and it is currently the treatment of choice for most patients. Skilled injectors will offer patients either Restylane ® or one of the Juvaderm ™ products, and it would be up to the injector to determine which of the HA fi llers they feel most comfortable injecting. Head-to-head comparison studies are lacking at this time. These types of studies would give physicians a better understanding of which HA fi ller works best for which patient and where each HA fi ller works better. Without these studies, it is physician preference and patient preference as to which products are used for patients.
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